Latham & Watkins Advises P3 Health Partners in US$2.3 Billion Merger with Foresight Acquisition Corp.

A corporate deal team advises on the transaction that will make P3 a publicly traded company.

May 25, 2021

P3 Health Partners (P3), a patient-centered and physician-led population health management company, and Foresight Acquisition Corp. (NASDAQ: FORE) (Foresight) have entered into a definitive agreement which would result in P3 becoming a publicly listed company. Upon closing of the transaction, the combined entity will be renamed P3 Health Partners and is expected to remain listed on the Nasdaq Capital Market.

Latham & Watkins LLP represents P3 Health Partners in the transaction with a corporate deal team led by Orange County/New York partner Charles Ruck, Orange County partner Scott Shean and Boston partner Wesley Holmes, with Orange County associate Brett Urig, Boston associate Jennifer Yoon and Orange County associates Christopher Martinez, Peter Bassine and Caitlin Nguyen. Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with Washington, D.C. associate Emmanuel Kassim; on benefits and compensation matters by Los Angeles partner Michelle Carpenter and Los Angeles counsel Aryeh Zuber, with Los Angeles associate Tara McCarney.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.